Covidien re-states Q1, Q2 financials on specialty chemical sale

June 14, 2010 by MassDevice staff

Covidien plc restates its first-quarter and second-quarter financials as it re-classifies its specialty chemicals business as a discontinued operation.

COV logo

Covidien plc (NYSE:COV) restated its financial results for the past two quarters after it re-classified its specialty chemicals business, sold to New Mountain Capital LLC last month, as a discontinued operation.

The Mansfield, Mass.-based medical products conglomerate had posted first-quarter sales of $2.75 billion during the three months ended Dec. 25, 2009. But after deducting $105 million in discontinued sales, the company is reporting Q1 sales of $2.64 billion, down 3.8 percent.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.